Organization | Osaka Medical College

Osaka Medical College Report issue

Academic/Hospital Phase 2 Phase 4

Founded: Takatsuki Japan (1927)

Organization Overview

First Clinical Trial

2007

NCT00569699

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2015

Timeline

NOW

Now

Alternative names

Department of Nuerosurgery, Osaka Medical College | Osaka Medical College Hospital

Active Ingredients

Drugs in Phase 4 Trials (2)

bevacizumab (avastin) (3 trials)

ranibizumab (lucentis) (1 trial)

Drugs in Phase 2 Trials (8)

gimeracil (2 trials)

oteracil (2 trials)

paclitaxel (taxol) (2 trials)

tegafur (2 trials)

temozolomide (temodar) (1 trial)

trastuzumab (herceptin) (1 trial)

troponin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Breast Neoplasms (Phase 2)

Central Nervous System Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 2)

Edema (Phase 4)

Glioblastoma (Phase 2)

Macular Edema (Phase 4)

Nervous System Neoplasms (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 6
# of Trial APIs: 10